fluoxetine has been researched along with nefazodone in 50 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 19 (38.00) | 18.2507 |
| 2000's | 16 (32.00) | 29.6817 |
| 2010's | 15 (30.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Carlier, PR; Lo, MM; Lo, PC; Reynolds, IJ; Richelson, E; Sharma, TA; Tatsumi, M | 1 |
| Dansette, PM; Fontana, E; Poli, SM | 1 |
| Benz, RD; Contrera, JF; Kruhlak, NL; Matthews, EJ; Weaver, JL | 1 |
| Barnes, JC; Bradley, P; Day, NC; Fourches, D; Reed, JZ; Tropsha, A | 1 |
| Choi, SS; Contrera, JF; Hastings, KL; Kruhlak, NL; Sancilio, LF; Weaver, JL; Willard, JM | 1 |
| Ang, KK; Arkin, MR; Chen, S; Doyle, PS; Engel, JC; McKerrow, JH | 1 |
| Fisk, L; Greene, N; Naven, RT; Note, RR; Patel, ML; Pelletier, DJ | 1 |
| Afshari, CA; Eschenberg, M; Hamadeh, HK; Lee, PH; Lightfoot-Dunn, R; Morgan, RE; Qualls, CW; Ramachandran, B; Trauner, M; van Staden, CJ | 1 |
| Ekins, S; Williams, AJ; Xu, JJ | 1 |
| Alelyunas, YW; Bui, K; Empfield, JR; McCarthy, D; Pelosi-Kilby, L; Shen, C; Spreen, RC | 1 |
| Chen, M; Fang, H; Liu, Z; Shi, Q; Tong, W; Vijay, V | 1 |
| Jung, ME; Kang, SY; Kim, HJ; Kim, J; Kim, MJ; Kim, MS; Lee, J; Lee, KN; Lee, M; Lee, SH; Park, EJ; Park, WK; Seo, HJ; Son, EJ | 1 |
| Artursson, P; Haglund, U; Karlgren, M; Kimoto, E; Lai, Y; Norinder, U; Vildhede, A; Wisniewski, JR | 1 |
| Ambroso, JL; Ayrton, AD; Baines, IA; Bloomer, JC; Chen, L; Clarke, SE; Ellens, HM; Harrell, AW; Lovatt, CA; Reese, MJ; Sakatis, MZ; Taylor, MA; Yang, EY | 1 |
| Cantin, LD; Chen, H; Kenna, JG; Noeske, T; Stahl, S; Walker, CL; Warner, DJ | 1 |
| Afshari, CA; Chen, Y; Dunn, RT; Hamadeh, HK; Kalanzi, J; Kalyanaraman, N; Morgan, RE; van Staden, CJ | 1 |
| Chen, M; Hu, C; Suzuki, A; Thakkar, S; Tong, W; Yu, K | 1 |
| Jones, LH; Nadanaciva, S; Rana, P; Will, Y | 1 |
| Ieni, JR; Knight, DL; Nemeroff, CB; Owens, MJ; Winders, K | 1 |
| Anton, SF; Revicki, DA | 1 |
| Preskorn, SH | 1 |
| Kaplita, SB; Marcus, RN; Roberts, DL; Robinson, DS; Seminara, JA; Smith, JM; Stringfellow, JC | 1 |
| Castañeda, R; Levy, R; Sussman, N; Westreich, LM | 1 |
| Brown, RE; Culpepper, L; Gonzales, J; Hales, RE; Keller, MB; Revicki, DA | 1 |
| Möller, HJ; Volz, HP | 1 |
| Armitage, R; Cole, D; Rush, AJ; Yonkers, K | 1 |
| Albala, BJ; Erman, MK; Gillin, JC; Rapaport, M; Winokur, A | 1 |
| Benazzi, F | 1 |
| Albala, BJ; Armitage, R; Erman, MK; Fleming, JB; Gillin, JC; Kaplita, SB; McQuade, RD; Moldofsky, H; Montplaisir, J; Rush, AJ; Vogel, GW; Winokur, A; Yonkers, KA | 1 |
| Richelson, E | 1 |
| Anton, SF; Bakish, D; Brown, RE; Feeny, D; Palmer, W; Revicki, DA; Rosser, WW | 1 |
| Benfield, P; Wilde, MI | 1 |
| Thase, ME | 1 |
| Churchill, E; Davidson, JR; Meltzer-Brody, S | 1 |
| Smith, DL; Wenegrat, BG | 1 |
| Davidson, JR | 1 |
| Dunn, NR; Freemantle, SN; Mackay, FR; Mann, RD; Martin, RM; Pearce, GL | 1 |
| Jurima-Romet, M; Neigh, S; Wright, M | 1 |
| Court, MH; Duan, SX; Greenblatt, DJ; Hesse, LM; Shader, RI; Venkatakrishnan, K; von Moltke, LL | 1 |
| Ferguson, JM | 1 |
| Baruch, Y; Chelben, J; Lustig, M; Strous, RD | 1 |
| Keller, MB | 1 |
| Alfaro, CL; Ereshefsky, L; Lam, YW; Miller, M | 1 |
| Cheng, KT; DeVane, CL; Donovan, JL; Liston, HL; Markowitz, JS; Risch, SC; Willard, L | 1 |
| Albert, PR; Bakish, D; Du, L; Hrdina, P; Lemonde, S | 1 |
| Martényi, F | 1 |
| Olivier, B; Schweitzer, DH; Waldinger, MD; Zwinderman, AH | 1 |
| Papakostas, GI; Shelton, RC | 1 |
| Kelly, BD | 1 |
| Cipriani, A; Coghill, D; Cohen, D; Cuijpers, P; Del Giovane, C; Hazell, P; Hetrick, SE; Leucht, S; Liu, L; Liu, Y; Michael, KD; Pu, J; Qin, B; Ravindran, AV; Whittington, C; Xie, P; Yang, L; Zhang, Y; Zhou, X | 1 |
13 review(s) available for fluoxetine and nefazodone
| Article | Year |
|---|---|
Cytochrome p450 enzymes mechanism based inhibitors: common sub-structures and reactivity.
Topics: Cytochrome P-450 Enzyme Inhibitors; Cytochrome P-450 Enzyme System; Drug Interactions; Enzyme Inhibitors; Humans; Isoenzymes; Structure-Activity Relationship; Terminology as Topic | 2005 |
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Drug Labeling; Humans; Pharmaceutical Preparations; Risk | 2016 |
Comparison of the tolerability of bupropion, fluoxetine, imipramine, nefazodone, paroxetine, sertraline, and venlafaxine.
Topics: 1-Naphthylamine; Antidepressive Agents; Bupropion; Clinical Trials as Topic; Cyclohexanols; Depressive Disorder; Drug Design; Drug Tolerance; Drugs, Investigational; Fluoxetine; Humans; Imipramine; Paroxetine; Piperazines; Selective Serotonin Reuptake Inhibitors; Sertraline; Triazoles; Venlafaxine Hydrochloride | 1995 |
The safety profile of nefazodone.
Topics: Adolescent; Adult; Age Factors; Aged; Antidepressive Agents, Second-Generation; Antidepressive Agents, Tricyclic; Clinical Trials as Topic; Cytochrome P-450 CYP3A; Cytochrome P-450 Enzyme System; Depressive Disorder; Double-Blind Method; Drug Interactions; Female; Fluoxetine; Humans; Imipramine; Male; Middle Aged; Mixed Function Oxygenases; Piperazines; Placebos; Sexual Dysfunctions, Psychological; Treatment Outcome; Triazoles; Weight Gain | 1996 |
Drug treatment of depression in the 1990s. An overview of achievements and future possibilities.
Topics: Antidepressive Agents; Antidepressive Agents, Second-Generation; Cyclohexanols; Depressive Disorder; Fluoxetine; Humans; Piperazines; Selective Serotonin Reuptake Inhibitors; Triazoles; Venlafaxine Hydrochloride | 1996 |
Pharmacokinetic interactions of antidepressants.
Topics: Antidepressive Agents; Cyclohexanols; Cytochrome P-450 CYP1A2; Cytochrome P-450 CYP2D6; Cytochrome P-450 CYP3A; Cytochrome P-450 Enzyme System; Depressive Disorder; Drug Interactions; Drug Therapy, Combination; Fluoxetine; Fluvoxamine; Humans; Mixed Function Oxygenases; Piperazines; Selective Serotonin Reuptake Inhibitors; Triazoles; Venlafaxine Hydrochloride | 1998 |
Fluoxetine. A pharmacoeconomic review of its use in depression.
Topics: Antidepressive Agents, Tricyclic; Depression; Fluoxetine; Health Care Costs; Humans; Piperazines; Quality of Life; Selective Serotonin Reuptake Inhibitors; Triazoles | 1998 |
Antidepressant treatment of the depressed patient with insomnia.
Topics: Antidepressive Agents, Tricyclic; Comorbidity; Cyclohexanols; Depressive Disorder; Fluoxetine; Humans; Mianserin; Mirtazapine; Piperazines; Selective Serotonin Reuptake Inhibitors; Serotonin Antagonists; Sleep; Sleep Initiation and Maintenance Disorders; Treatment Outcome; Triazoles; Venlafaxine Hydrochloride | 1999 |
Pharmacotherapy of posttraumatic stress disorder: treatment options, long-term follow-up, and predictors of outcome.
Topics: Anticonvulsants; Antidepressive Agents, Tricyclic; Clinical Trials as Topic; Fluoxetine; Follow-Up Studies; Humans; Monoamine Oxidase Inhibitors; Paroxetine; Piperazines; Selective Serotonin Reuptake Inhibitors; Serotonin Antagonists; Stress Disorders, Post-Traumatic; Treatment Outcome; Triazoles | 2000 |
The effects of antidepressants on sexual functioning in depressed patients: a review.
Topics: Adult; Antidepressive Agents; Bupropion; Clinical Trials as Topic; Depressive Disorder; Double-Blind Method; Female; Fluoxetine; Humans; Male; Piperazines; Selective Serotonin Reuptake Inhibitors; Sertraline; Sexual Behavior; Sexual Dysfunctions, Psychological; Sexuality; Single-Blind Method; Triazoles | 2001 |
[Three paradigms in the treatment of posttraumatic stress disorder].
Topics: Anti-Anxiety Agents; Antidepressive Agents, Second-Generation; Benzodiazepines; Combat Disorders; Controlled Clinical Trials as Topic; Female; Fluoxetine; Humans; Hypnotics and Sedatives; Male; Piperazines; Selective Serotonin Reuptake Inhibitors; Stress Disorders, Post-Traumatic; Stress Disorders, Traumatic, Acute; Triazoles | 2005 |
Augmentation of antidepressants with atypical antipsychotics for treatment-resistant major depressive disorder.
Topics: Antidepressive Agents; Antipsychotic Agents; Aripiprazole; Benzodiazepines; Depressive Disorder, Major; Dibenzothiazepines; Dopamine D2 Receptor Antagonists; Drug Resistance; Drug Therapy, Combination; Fluoxetine; Humans; Olanzapine; Piperazines; Quetiapine Fumarate; Quinolones; Serotonin 5-HT2 Receptor Antagonists; Thiazoles; Trazodone; Triazoles | 2008 |
Comparative efficacy and tolerability of antidepressants for major depressive disorder in children and adolescents: a network meta-analysis.
Topics: Adolescent; Amitriptyline; Antidepressive Agents; Bayes Theorem; Child; Citalopram; Clomipramine; Confounding Factors, Epidemiologic; Depressive Disorder, Major; Desipramine; Double-Blind Method; Drug Administration Schedule; Duloxetine Hydrochloride; Evidence-Based Medicine; Fluoxetine; Humans; Imipramine; Mianserin; Mirtazapine; Nortriptyline; Paroxetine; Piperazines; Randomized Controlled Trials as Topic; Research Design; Sertraline; Treatment Outcome; Triazoles; Venlafaxine Hydrochloride | 2016 |
6 trial(s) available for fluoxetine and nefazodone
| Article | Year |
|---|---|
A multicenter, double-blind comparison of the effects of nefazodone and fluoxetine on sleep architecture and quality of sleep in depressed outpatients.
Topics: Adult; Antidepressive Agents, Second-Generation; Depressive Disorder; Double-Blind Method; Female; Fluoxetine; Humans; Male; Middle Aged; Outpatients; Piperazines; Selective Serotonin Reuptake Inhibitors; Sleep Stages; Sleep, REM; Triazoles | 1997 |
A comparison of nefazodone and fluoxetine on mood and on objective, subjective, and clinician-rated measures of sleep in depressed patients: a double-blind, 8-week clinical trial.
Topics: Adult; Affect; Ambulatory Care; Antidepressive Agents, Second-Generation; Depressive Disorder; Double-Blind Method; Female; Fluoxetine; Humans; Male; Middle Aged; Personality Inventory; Piperazines; Placebos; Polysomnography; Psychiatric Status Rating Scales; Sleep; Sleep Wake Disorders; Treatment Outcome; Triazoles | 1997 |
Comparative effects of nefazodone and fluoxetine on sleep in outpatients with major depressive disorder.
Topics: Adult; Ambulatory Care; Antidepressive Agents, Second-Generation; Circadian Rhythm; Comorbidity; Depressive Disorder; Double-Blind Method; Electroencephalography; Female; Fluoxetine; Humans; Male; Middle Aged; Piperazines; Receptors, Serotonin; Selective Serotonin Reuptake Inhibitors; Sleep; Sleep Initiation and Maintenance Disorders; Sleep, REM; Triazoles; Wakefulness | 1998 |
Derivation of the SPAN, a brief diagnostic screening test for post-traumatic stress disorder.
Topics: Adult; Antidepressive Agents; Cohort Studies; Combat Disorders; Disasters; Female; Fluoxetine; Fluvoxamine; Humans; Lamotrigine; Male; Middle Aged; Personality Inventory; Piperazines; Psychometrics; Rape; Reproducibility of Results; Stress Disorders, Post-Traumatic; Triazines; Triazoles | 1999 |
Pharmacokinetic and pharmacodynamic interactions of oral midazolam with ketoconazole, fluoxetine, fluvoxamine, and nefazodone.
Topics: Administration, Oral; Adult; Analysis of Variance; Area Under Curve; Cytochrome P-450 CYP3A; Cytochrome P-450 Enzyme System; Drug Interactions; Female; Fluoxetine; Fluvoxamine; Humans; Ketoconazole; Male; Midazolam; Piperazines; Triazoles | 2003 |
Comparative CYP3A4 inhibitory effects of venlafaxine, fluoxetine, sertraline, and nefazodone in healthy volunteers.
Topics: Administration, Oral; Adult; Alprazolam; Area Under Curve; Breath Tests; Carbon Radioisotopes; Cross-Over Studies; Cyclohexanols; Cytochrome P-450 CYP3A; Cytochrome P-450 Enzyme Inhibitors; Cytochrome P-450 Enzyme System; Delayed-Action Preparations; Drug Administration Schedule; Erythromycin; Fluoxetine; Half-Life; Humans; Male; Middle Aged; Molecular Probes; Piperazines; Sertraline; Triazoles; Venlafaxine Hydrochloride | 2004 |
31 other study(ies) available for fluoxetine and nefazodone
| Article | Year |
|---|---|
Synthesis of a potent wide-spectrum serotonin-, norepinephrine-, dopamine-reuptake inhibitor (SNDRI) and a species-selective dopamine-reuptake inhibitor based on the gamma-amino alcohol functional group.
Topics: Amino Alcohols; Animals; Antidepressive Agents; Dopamine; Humans; Neurotransmitter Uptake Inhibitors; Norepinephrine; Rats; Serotonin; Species Specificity | 1998 |
Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.
Topics: Adverse Drug Reaction Reporting Systems; Artificial Intelligence; Computers; Databases, Factual; Drug Prescriptions; Drug-Related Side Effects and Adverse Reactions; Endpoint Determination; Models, Molecular; Quantitative Structure-Activity Relationship; Software; United States; United States Food and Drug Administration | 2004 |
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.
Topics: Animals; Chemical and Drug Induced Liver Injury; Cluster Analysis; Databases, Factual; Humans; MEDLINE; Mice; Models, Chemical; Molecular Conformation; Quantitative Structure-Activity Relationship | 2010 |
Development of a phospholipidosis database and predictive quantitative structure-activity relationship (QSAR) models.
Topics: | 2008 |
Image-based high-throughput drug screening targeting the intracellular stage of Trypanosoma cruzi, the agent of Chagas' disease.
Topics: Animals; Cattle; Cell Line; Cell Line, Tumor; Chagas Disease; Drug Evaluation, Preclinical; Hepatocytes; High-Throughput Screening Assays; Humans; Image Processing, Computer-Assisted; Muscle, Skeletal; Parasitic Sensitivity Tests; Trypanocidal Agents; Trypanosoma cruzi | 2010 |
Developing structure-activity relationships for the prediction of hepatotoxicity.
Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Humans; Structure-Activity Relationship; Tetracyclines; Thiophenes | 2010 |
Interference with bile salt export pump function is a susceptibility factor for human liver injury in drug development.
Topics: Animals; ATP Binding Cassette Transporter, Subfamily B, Member 11; ATP-Binding Cassette Transporters; Biological Assay; Biological Transport; Cell Line; Cell Membrane; Chemical and Drug Induced Liver Injury; Cytoplasmic Vesicles; Drug Evaluation, Preclinical; Humans; Liver; Rats; Reproducibility of Results; Spodoptera; Transfection; Xenobiotics | 2010 |
A predictive ligand-based Bayesian model for human drug-induced liver injury.
Topics: Bayes Theorem; Chemical and Drug Induced Liver Injury; Humans; Ligands | 2010 |
Experimental solubility profiling of marketed CNS drugs, exploring solubility limit of CNS discovery candidate.
Topics: Central Nervous System Agents; Drug Evaluation, Preclinical; Hydrogen-Ion Concentration; Pharmaceutical Preparations; Solubility | 2010 |
FDA-approved drug labeling for the study of drug-induced liver injury.
Topics: Animals; Benchmarking; Biomarkers, Pharmacological; Chemical and Drug Induced Liver Injury; Drug Design; Drug Labeling; Drug-Related Side Effects and Adverse Reactions; Humans; Pharmaceutical Preparations; Reproducibility of Results; United States; United States Food and Drug Administration | 2011 |
Design and synthesis of novel arylpiperazine derivatives containing the imidazole core targeting 5-HT(2A) receptor and 5-HT transporter.
Topics: Animals; Antidepressive Agents; Binding, Competitive; CHO Cells; Cricetinae; Cricetulus; Drug Design; Humans; Imidazoles; Male; Mice; Motor Activity; Piperazines; Radioligand Assay; Rats; Rats, Sprague-Dawley; Receptor, Serotonin, 5-HT2A; Selective Serotonin Reuptake Inhibitors; Serotonin 5-HT2 Receptor Antagonists; Serotonin Plasma Membrane Transport Proteins; Stereoisomerism; Structure-Activity Relationship | 2011 |
Classification of inhibitors of hepatic organic anion transporting polypeptides (OATPs): influence of protein expression on drug-drug interactions.
Topics: Atorvastatin; Biological Transport; Drug Interactions; Estradiol; Estrone; HEK293 Cells; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; In Vitro Techniques; Least-Squares Analysis; Liver; Liver-Specific Organic Anion Transporter 1; Models, Molecular; Multivariate Analysis; Organic Anion Transporters; Organic Anion Transporters, Sodium-Independent; Protein Isoforms; Pyrroles; Solute Carrier Organic Anion Transporter Family Member 1B3; Structure-Activity Relationship; Transfection | 2012 |
Preclinical strategy to reduce clinical hepatotoxicity using in vitro bioactivation data for >200 compounds.
Topics: Chemical and Drug Induced Liver Injury; Cytochrome P-450 Enzyme Inhibitors; Cytochrome P-450 Enzyme System; Decision Trees; Drug Evaluation, Preclinical; Drug-Related Side Effects and Adverse Reactions; Glutathione; Humans; Liver; Pharmaceutical Preparations; Protein Binding | 2012 |
Mitigating the inhibition of human bile salt export pump by drugs: opportunities provided by physicochemical property modulation, in silico modeling, and structural modification.
Topics: Animals; ATP Binding Cassette Transporter, Subfamily B, Member 11; ATP-Binding Cassette Transporters; Bile Acids and Salts; Cell Line; Chemical and Drug Induced Liver Injury; Humans; Quantitative Structure-Activity Relationship | 2012 |
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
Topics: Animals; ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Transporter, Subfamily B, Member 11; ATP-Binding Cassette Transporters; Biological Transport; Chemical and Drug Induced Liver Injury; Cluster Analysis; Drug-Related Side Effects and Adverse Reactions; Humans; Liver; Male; Multidrug Resistance-Associated Proteins; Pharmacokinetics; Rats; Rats, Sprague-Dawley; Recombinant Proteins; Risk Assessment; Risk Factors; Toxicity Tests | 2013 |
Development of a cell viability assay to assess drug metabolite structure-toxicity relationships.
Topics: Adenosine Triphosphate; Benzbromarone; Cell Line; Cell Survival; Chromans; Cytochrome P-450 CYP2C9; Cytochrome P-450 CYP2D6; Cytochrome P-450 CYP3A; Cytochrome P-450 Enzyme System; Humans; Pharmaceutical Preparations; Thiazolidinediones; Troglitazone | 2016 |
The serotonergic antidepressant nefazodone inhibits the serotonin transporter: in vivo and ex vivo studies.
Topics: Animals; Antidepressive Agents; Carrier Proteins; Cerebral Cortex; Dose-Response Relationship, Drug; Fluoxetine; Male; Membrane Glycoproteins; Membrane Transport Proteins; Nerve Tissue Proteins; p-Chloroamphetamine; Piperazines; Rats; Rats, Sprague-Dawley; Serotonin; Serotonin Plasma Membrane Transport Proteins; Synaptosomes; Triazoles | 1995 |
The use of decision analysis in the pharmacoeconomic evaluation of an antidepressant: a cost-effectiveness study of nefazodone.
Topics: Antidepressive Agents; Cost-Benefit Analysis; Decision Support Techniques; Economics, Pharmaceutical; Fluoxetine; Follow-Up Studies; Humans; Imipramine; Models, Economic; Piperazines; Treatment Outcome; Triazoles | 1995 |
Drug craving and other negative reactions after abrupt substitution of nefazodone for other serotonergic agents.
Topics: Antidepressive Agents, Second-Generation; Cyclohexanols; Drug Administration Schedule; Female; Fluoxetine; Humans; Male; Paroxetine; Piperazines; Recurrence; Serotonin Agents; Substance-Related Disorders; Triazoles; Venlafaxine Hydrochloride | 1996 |
Cost-effectiveness of newer antidepressants compared with tricyclic antidepressants in managed care settings.
Topics: Antidepressive Agents; Antidepressive Agents, Tricyclic; Cost Savings; Cost-Benefit Analysis; Decision Support Techniques; Depressive Disorder; Drug Costs; Fluoxetine; Health Care Costs; Health Policy; Health Services; Humans; Imipramine; Managed Care Programs; Patient Compliance; Piperazines; Probability; Quality-Adjusted Life Years; Treatment Failure; Treatment Outcome; Triazoles | 1997 |
Dangerous interaction with nefazodone added to fluoxetine, desipramine, venlafaxine, valproate and clonazepam combination therapy.
Topics: Adult; Antidepressive Agents; Clonazepam; Cyclohexanols; Depressive Disorder; Desipramine; Drug Therapy, Combination; Female; Fluoxetine; Humans; Hypotension; Panic Disorder; Piperazines; Substance Withdrawal Syndrome; Triazoles; Venlafaxine Hydrochloride | 1997 |
Modelling the cost effectiveness of antidepressant treatment in primary care.
Topics: Antidepressive Agents; Decision Support Techniques; Depressive Disorder; Female; Fluoxetine; Humans; Imipramine; Markov Chains; Models, Economic; Piperazines; Primary Health Care; Quality-Adjusted Life Years; Sensitivity and Specificity; Triazoles | 1995 |
A case report of serotonin syndrome associated with combined nefazodone and fluoxetine.
Topics: Antidepressive Agents, Second-Generation; Bipolar Disorder; Drug Therapy, Combination; Fluoxetine; Humans; Male; Middle Aged; Piperazines; Selective Serotonin Reuptake Inhibitors; Serotonin Syndrome; Triazoles | 2000 |
Newer antidepressants: a comparison of tolerability in general practice.
Topics: Adult; Aged; Antidepressive Agents; Cohort Studies; Cyclohexanols; Depressive Disorder; Family Practice; Female; Fluoxetine; Humans; Male; Middle Aged; Moclobemide; Paroxetine; Piperazines; Selective Serotonin Reuptake Inhibitors; Sertraline; Triazoles; Venlafaxine Hydrochloride | 1999 |
Terfenadine-antidepressant interactions: an in vitro inhibition study using human liver microsomes.
Topics: Alkylation; Antidepressive Agents, Second-Generation; Biotransformation; Chromatography, High Pressure Liquid; Cytochrome P-450 CYP3A; Cytochrome P-450 Enzyme System; Drug Interactions; Fluoxetine; Histamine H1 Antagonists; Humans; Hydroxylation; Microsomes, Liver; Mixed Function Oxygenases; Piperazines; Sertraline; Terfenadine; Triazoles | 1998 |
CYP2B6 mediates the in vitro hydroxylation of bupropion: potential drug interactions with other antidepressants.
Topics: Antibodies; Antidepressive Agents, Second-Generation; Aryl Hydrocarbon Hydroxylases; Biotransformation; Bupropion; Chromatography, High Pressure Liquid; Cytochrome P-450 CYP2B6; Cytochrome P-450 Enzyme System; Dose-Response Relationship, Drug; Drug Interactions; Fluoxetine; Fluvoxamine; Humans; Hydroxylation; Isoenzymes; Kinetics; Microsomes, Liver; Oxidoreductases, N-Demethylating; Paroxetine; Piperazines; Sertraline; Triazoles | 2000 |
Remission of SSRI-induced akathisia after switch to nefazodone.
Topics: Adult; Akathisia, Drug-Induced; Antidepressive Agents, Second-Generation; Depressive Disorder; Drug Administration Schedule; Female; Fluoxetine; Humans; Paroxetine; Piperazines; Selective Serotonin Reuptake Inhibitors; Triazoles | 2001 |
Long-term treatment of recurrent and chronic depression.
Topics: Antidepressive Agents; Chronic Disease; Clinical Trials as Topic; Cognitive Behavioral Therapy; Combined Modality Therapy; Cost of Illness; Depressive Disorder; Disability Evaluation; Drug Administration Schedule; Fluoxetine; Humans; Piperazines; Placebos; Recurrence; Treatment Outcome; Triazoles | 2001 |
Association of the C(-1019)G 5-HT1A functional promoter polymorphism with antidepressant response.
Topics: Adrenergic beta-Antagonists; Adult; Alleles; Antidepressive Agents; Antidepressive Agents, Second-Generation; Benzimidazoles; Cohort Studies; Depressive Disorder; Drug Therapy, Combination; Female; Fluoxetine; Humans; Male; Middle Aged; Pindolol; Piperazines; Polymorphism, Genetic; Promoter Regions, Genetic; Psychiatric Status Rating Scales; Receptor, Serotonin, 5-HT1A; Triazoles | 2004 |
Geometric mean IELT and premature ejaculation: appropriate statistics to avoid overestimation of treatment efficacy.
Topics: Antidepressive Agents; Coitus; Data Interpretation, Statistical; Ejaculation; Fluoxetine; Fluvoxamine; Humans; Male; Mianserin; Mirtazapine; Models, Biological; Piperazines; Reaction Time; Research Design; Selective Serotonin Reuptake Inhibitors; Sensitivity and Specificity; Sertraline; Sexual Dysfunction, Physiological; Treatment Outcome; Triazoles | 2008 |
Do new-generation antidepressants work?
Topics: Antidepressive Agents, Second-Generation; Cyclohexanols; Depression; Fluoxetine; Humans; Paroxetine; Piperazines; Treatment Outcome; Triazoles; Venlafaxine Hydrochloride | 2008 |